SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 76.78 |
| Enterprise Value ($M) | 23.36 |
| Book Value ($M) | 1.05 |
| Book Value / Share | 0.01 |
| Price / Book | 73.19 |
| NCAV ($M) | -7.92 |
| NCAV / Share | -0.06 |
| Price / NCAV | -9.69 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.29 |
| Return on Assets (ROA) | -0.33 |
| Return on Equity (ROE) | -2.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.35 |
| Current Ratio | 2.35 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 160.56 |
| Assets | 169.53 |
| Liabilities | 168.48 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Bain Capital Life Sciences Fund II, L.P. | 4.00 | 22.92 | |
| 13G/A | Nextech Crossover I GP S.a r.l. | 9.80 | 93.11 | |
| 13G/A | Balyasny Asset Management Llc | 0.44 | -94.48 | |
| 13G/A | Silverarc Capital Management, Llc | 1.43 | -72.68 | |
| 13G/A | Orbimed Advisors Llc | 0.00 | -100.00 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.40 | 17.05 | |
| 13G/A | Avoro Capital Advisors LLC | 0.00 | -100.00 | |
| 13G | Vanguard Group Inc | 5.17 | 40.20 | |
| 13G/A | BlackRock, Inc. | 6.50 | 4.70 | |
| 13G/A | State Street Corp | 1.93 | -60.22 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,742,867 | 9,276,450 | 40.35 | |
| 7,686,616 | 17,752,616 | 43.30 | |
| 16,251,494 | 44,331,160 | 36.66 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MLYS – Mineralys Therapeutics, Inc. | MNMD – Mind Medicine (MindMed) Inc. |
| MRNA – Moderna, Inc. | MRVI – Maravai LifeSciences Holdings, Inc. |
| MYGN – Myriad Genetics, Inc. |
Financial data and stock pages provided by
Fintel.io